KEGG   DRUG: Teplizumab
Entry
D09013                      Drug                                   

Name
Teplizumab (USAN/INN)
Formula
C6462H9938N1738O2022S46
Exact mass
145709.5404
Mol weight
145799.4725
Sequence
(Heavy chain)
QVQLVQSGGG VVQPGRSLRL SCKASGYTFT RYTMHWVRQA PGKGLEWIGY INPSRGYTNY
NQKVKDRFTI SRDNSKNTAF LQMDSLRPED TGVYFCARYY DDHYCLDYWG QGTPVTVSSA
STKGPSVFPL APSSKSTSGG TAALGCLVKD YFPEPVTVSW NSGALTSGVH TFPAVLQSSG
LYSLSSVVTV PSSSLGTQTY ICNVNHKPSN TKVDKKVEPK SCDKTHTCPP CPAPEAAGGP
SVFLFPPKPK DTLMISRTPE VTCVVVDVSH EDPEVKFNWY VDGVEVHNAK TKPREEQYNS
TYRVVSVLTV LHQDWLNGKE YKCKVSNKAL PAPIEKTISK AKGQPREPQV YTLPPSRDEL
TKNQVSLTCL VKGFYPSDIA VEWESNGQPE NNYKTTPPVL DSDGSFFLYS KLTVDKSRWQ
QGNVFSCSVM HEALHNHYTQ KSLSLSPGK
(Light chain)
DIQMTQSPSS LSASVGDRVT ITCSASSSVS YMNWYQQTPG KAPKRWIYDT SKLASGVPSR
FSGSGSGTDY TFTISSLQPE DIATYYCQQW SSNPFTFGQG TKLQITRTVA APSVFIFPPS
DEQLKSGTAS VVCLLNNFYP REAKVQWKVD NALQSGNSQE SVTEQDSKDS TYSLSSTLTL
SKADYEKHKV YACEVTHQGL SSPVTKSFNR GEC
(Disulfide bridge: H22-H96, H146-H202, H263-H323, H369-H427, H228-H'228, H222-L213, L23-L87, L133-L193)
  Type
Peptide
Efficacy
Antidiabetic, Anti-CD3 antibody
Comment
Monoclonal antibody
Type I diabetes
Target
CD3 [HSA:915 916 917] [KO:K06450 K06451 K06452]
  Pathway
hsa04660  T cell receptor signaling pathway
Brite
Target-based classification of drugs [BR:br08310]
 Cell surface molecules and ligands
  Other cell surface molecules
   CD molecules
    CD3
     D09013  Teplizumab (USAN/INN)
Other DBs
CAS: 876387-05-2
PubChem: 96025696
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system